期刊文献+

微生物在精神分裂症发病机制的研究现状 被引量:4

Status of research on microorganisms in pathogenesis of schizophrenia
原文传递
导出
摘要 脑和肠道微生物群之间的相互作用逐渐被揭示。目前已经提出脑-肠轴失调和异常与各种中枢神经系统疾病有关。精神分裂症是一种病因不明的严重精神障碍。最近研究表明,肠道微生物的组成和数量变化会通过肠道菌群-肠-脑轴影响人类的认知和社会行为,这意味着肠道菌群在精神分裂症患者中可能起着重要的作用,并有望成为精神分裂症新的治疗靶点。本文综述了肠道菌群与精神分裂症相关性的研究进展,为预防和治疗精神分裂症等精神障碍类疾病提供了理论依据。 The interaction between the brain and intestinal microbiota has been gradually revealed, and it has been proposed that brain-gut axis disorders and abnormalities are related to various central nervous system diseases. Schizophrenia is a serious mental disorder with unknown etiology. Recent studies have shown that changes in the composition and quantity of intestinal microbial flora can affect human cognition and social behavior through the intestinal flora-gut-brain axis, which means that intestinal flora may play a role in patients with schizophrenia, and is expected to become a new therapeutic target for schizophrenia. This article reviews the progress in research on the relationship between intestinal flora and schizophrenia, and provides a theoretical basis for the prevention and treatment of mental disorders such as schizophrenia.
作者 黄小宇 孙诗倩 黎雪梅 HUANG Xiaoyu;SUN Shiqian;LI Xuemei(The Fourth People′s Hospital of Chengdu,Chengdu,Sichuan 610036,China)
出处 《中国微生态学杂志》 CAS CSCD 2020年第1期108-111,共4页 Chinese Journal of Microecology
关键词 微生物群 脑-肠轴 精神障碍 精神分裂症 Microbiota Brain-gut axis Psychiatric disorders Schizophrenia
  • 相关文献

参考文献2

二级参考文献28

  • 1谭云龙,周东丰,邹义壮,曹连元,苏建民,姚付新.精神分裂症迟发性运动障碍患者血清脑源性神经营养因子水平研究[J].中国神经精神疾病杂志,2004,30(5):332-334. 被引量:7
  • 2Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease [ J ]. Cell, 2008 ; 134:714 - 716.
  • 3Petrella JR, Mattay VS, Doraiswamy PM. Imaging genetics of brain longevity and mental wellness: the next frontier? [ J]. Radiology , 2008 ;246:20 - 32.
  • 4Kaddurah -Daouk R, Krishnan KR. Metabolomics: A global bio- chemical approach to the study of central nervous system diseases [ J]. Neuropsychopharma , 2009 ;34 : 173 - 186.
  • 5Griffin JL, Salek RM. Metabolomic applications to neuroscience: more challenges than chances? [ J]. Expert Rev Proteomics, 2007 ; 4:435 - 437.
  • 6Dunekley T, Coon KD, Stephan DA. Discovery and development of biomarkers of neurological disease[ J]. Drug Discov Today, 2005; 10:326 - 334.
  • 7Marchi N, Cavaglia M, Fazioa , et al. Peripheral markers of blood - brain barrier damage [ J ]. Clinica Chimica Acta, 2004 ; 342:1 - 12.
  • 8Karrenbauer VD, Leoni V, Lim ET, et al. Plasma cereboserol and maetic resonance imaging measures in mutiple sclerosis[ J]. Clin Neurol Neurosurg,2006 ; 108:456 -460.
  • 9Kaddurah - Daouk R, McEvoy J, Baillie RA, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia[ J]. Mol Psychiatry,2007 ; 12 : 934 - 45.
  • 10Yao JK, Dougherty, Reddy RD, et al. Altered interactions of tryp- tophan metabolites in first - episode neuroleptic - naive patients with schizophrenia[ J]. Mol Psychiatry,2010 ; 15 : 938 - 953.

共引文献8

同被引文献46

引证文献4

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部